Список литературы

2687-0940

Challenges in modern medicine

2687-0940

10.52575/2687-0940-2023-46-2-123-143

150

INTERNAL DISEASES

<strong>Obesity and Associated Diseases – Problematic Issues of Pathogenesis and Modern Strategies for Diagnosis and Treatment</strong>

Golivets

Tatyana P.

Golivets

Tatyana P.

golivets@ya.ru

Dubonosova

Diana G.

Dubonosova

Diana G.

ya.diana-art@yandex.ru

Likrizon

Sergey V.

Likrizon

Sergey V.

likrizonendo@mail.ru

2023

46200

The study of the mechanisms of the pathological influence of obesity on the development, course and outcomes of a number of socially significant diseases, the search for effective ways for their treatment and prevention, remain among the priorities for modern medical science and healthcare. The information accumulated on this problem over the past decades demonstrates the need for a new strategy for clinical practice, with the introduction of interdisciplinary approaches to the diagnosis of obesity and associated pathology with the inclusion of detailed metabolic phenotyping of obese individuals and a personalized approach to treatment. The task of timely determination of the degree of cardiovascular risk in obese patients, early diagnosis of carbohydrate metabolism disorders, selection of methods for safe treatment of obesity and the development of effective measures for the prevention of its chronic complications is acute for practical healthcare specialists. This review analyzes the literature materials on the pathogenesis of obesity and associated diseases and formulates modern strategic approaches to the diagnosis, treatment and prevention of this pathology.

obesityassociated diseasespathogenetic mechanismsleptin resistancedrug therapy

Список литературы

Ametov A.S. 2019. Ozhirenie. Sovremenny`j vzglyad na patogenez i terapiyu [Fatness. Modern view on pathogenesis and therapy]. Tom 1. Moskva. Izd. Goe`tar-Media. 384 s.

Axmedov V.A., Goloktionova A.A., Isaeva A.S. 2019. Ozhirenie i mikrobiota kishechnika [Obesity and gut microbiota]. Lechashhij vrach. 7: 68–71.

Bershtejn L.M., Kovalenko I.G. 2010. «Metabolicheski zdorovy`e» licza s ozhireniem i metabolicheskie priznaki ozhireniya u licz s normal`noj massoj tela: chto za e`tim stoit? ["Metabolically healthy" obese individuals and metabolic signs of obesity in individuals with normal body weight: what is behind this?] Problemy` e`ndokrinologii. 3: 47–51.

Biryukova E.V., Platonova N.M. 2019. Ozhirenie: sostoyanie problemy` i vozmozhnosti terapii v XXI veke [Obesity: the state of the problem and the possibilities of therapy in the XXI century]. E`ffektivnaya farmakoterapiya. 15 (41): 32–40.

Borodkina D.A., Gruzdeva O.V., Kvitkova L.V., Barbarash O.L. 2017. Raspredelenie zhirovy`x otlozhenij: razgadka kazhushhegosya paradoksa ozhireniya v kardiologii? [Distribution of body fat: the solution to the apparent paradox of obesity in cardiology?] Ozhirenie i metabolizm. 14 (2): 3–8.

Butrova S.A., Ploxaya A.A. 2020. Lechenie ozhireniya: sovremenny`e aspekty`[Treatment of obesity: modern aspects]. RMZh. Medicinskoe obozrenie. 5. https://www.rmj.ru/articles/endokrinologiya/Lechenie_oghireniya_sovremennye_aspekty/

Gruzdeva O.V., Akbasheva O.E., Dy`lev Yu.A. 2017. Adipokinovy`j i citokinovy`j profili e`pikardial`noj i podkozhnoj zhirovoj tkani u pacientov s ishemicheskoj bolezn`yu serdcza [Adipokine and cytokine profiles of epicardial and subcutaneous adipose tissue in patients with coronary heart disease]. Byulleten` e`ksperimental`noj biologii i mediciny`. 163 (5): 560–563.

Dedov I.I., Mokry`sheva N.G., Mel`nichenko G.A., Troshina E.A. 2021. Ozhirenie. Klinicheskie rekomendacii [Fatness. Clinical recommendations]. Consilium Medicum. 2021; 23 (4): 311–325. doi: 10.26442/20751753.2021.4.200832

Drapkina O.M., Samorodskaya I.V., Starinskaya M.A., Kim O.T., Nejmark A.E. 2021. Ozhirenie: ocenka i taktika vedeniya pacientov [Obesity: assessment and tactics of patient management]. Kollektivnaya monografiya. M.: FGBU “NMICz TPM” Minzdrava Rossii; OOO “Siliceya-Poligraf”. 174 s.

Dreval` A.V. 2018. Diabetologicheskaya praktika. Rukovodstvo dlya vrachej [Diabetological practice]. Moskva. GE`OTAR-Media. 544 s. ISBN 978-5-9704-4193-0.

Kuprienko N.B., Smirnova N.N. 2015. Vitamin D, ozhirenie i risk kadiorenal`ny`x narushenij u detej [Vitamin D, obesity and the risk of cadiorenal disorders in children]. Arterial`naya gipertenziya. 21 (1): 48–58.

Nedogoda S.V., Vyortkin A.L., Naumov A.V. 2016. Ozhirenie i komorbidnaya patologiya v praktike poliklinicheskogo vracha (opredelenie, diagnostika; nemedikamentoznoe lechenie; lechenie ozhireniya i komorbidnoj patologii) [Obesity and comorbid pathology in the practice of a polyclinic doctor (definition, diagnosis; non-drug treatment; treatment of obesity and comorbid pathology)]. T. 2. 1 (4): 4–33.

Samorodskaya I.V. 2014. Indeks massy` tela i paradoks ozhireniya [Body mass index and the obesity paradox]. RMZh. Kardiologiya. 2: 170.

Simanenkov V.I., Tixonov S.V., Il`yashevich I.G. 2017. E`pidemiologiya, social`ny`e aspekty` i patogenez ozhireniya [Epidemiology, social aspects and pathogenesis of obesity]. Vestnik Severo-Zapadnogo gosudarstvennogo medicinskogo universiteta im. I.I. Mechnikova. 21–27.

Timasheva Ya.R., Balxiyarova Zh.R., Kochetova O.V. 2021. Sovremennoe sostoyanie issledovanij v oblasti ozhireniya: geneticheskie aspekty`, rol` mikrobioma i predraspolozhennost` k COVID-19 [The current state of research in the field of obesity: genetic aspects, the role of the microbiome and predisposition to COVID-19]. Problemy` e`ndokrinologii. 67 (4): 20–35. doi: https://doi.org/10.14341/probl12775

Troshina E.A., Ershova E.V. 2018. Farmakoterapiya ozhireniya: chto novogo? [Pharmacotherapy of obesity: what's new?] Problemy` e`ndokrinologii. 64 (4): 270–276. https://doi.org/10.14341/probl9315

Filatova G.A., De`pyui T.I., Grishina T.I. 2018. Ozhirenie: sporny`e voprosy`, opredelyayushhie metabolicheskoe zdorov`e [Obesity: Controversial questions determining metabolic health]. E`ndokrinologiya: novosti, mneniya, obuchene. 7 (1): 58–67.

Chumakova G.A. 2016. Metody` ocenki visceral`nogo ozhireniya v klinicheskoj praktike [Methods of evaluation of visceral obesity in clinical practice]. Rossijskij kardiologicheskij zhurnal. 4: 89–96.

Shvarcz V.Ya. 2013. Vospalenie zhirovoj tkani: vrag ili drug? [Inflammation of adipose tissue: enemy or friend?] Citokiny` i vospalenie. 12 (1–2): 13–21.

Shlyaxto E.V., Nedogoda S.V., Konradi A.O., Baranova E.I. 2016. Koncepciya novy`x nacional`ny`x klinicheskix rekomendacij po ozhireniyu [The concept of new national clinical guidelines on obesity]. Rossijskij kardiologicheskij zhurnal. 4 (132): 7–13. http://dx.doi.org/10.15829/1560-4071-2016-4-7-13.

Abarca-Gómez L., Abdeen Z.A., Hamid Z.A. 2017. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. The Lancet. 390 (10113): 2627–2642. doi: 10.1016/s0140-6736(17)32129-3.

Al‐Daghri N.M. 2013. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. European journal of clinical investigation. 43 (2): 183–189.

Appleton S.L., Seaborn C.J., Visvanathan R., Hill C.L. 2013. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 36: 2388–2394.

Baker A.R., Silva N.F., Quinn D.W. 2006. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc. Diabetol. 13 (5): 1–16.

Castro H., Pomar C.A., Picó C. 2015. Cafeteria diet overfeeding in young male rats impairs the adaptive response to fed/fasted conditions and increases adiposity independent of body weight. Int. J. Obes. (Lond). 39 (3): 430–437.

Fain J.N. 2003. Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300: 674–678.

Fitzgibbons Timothy P., Czech Michael P. 2014. Epicardial and Perivascular Adipose Tissues and Their Influence on Cardiovascular Disease: Basic Mechanisms and Clinical Associations. J. Am. Heart Assoc. 3:e000582.

Fretts A.M., Howard B.V., Siscovick D.S. 2016. Processed Meat, but Not unprocessed Red Meat, Is Inversely Associated with Leukocyte Telomere Length in the Strong Heart Family Study. J. Nutr. J. Obes. 12: 63–71.

Garvey W. Garber Alan J., Mechanick Jeffrey I., Bray George A., Dagogo-Jack Samuel, Einhorn Daniel, Grunberger George, Handelsman Yehuda, Hennekens Charles H., Hurley Daniel L., McGill Janet, Palumbo Pasquale, Umpierrez Guillermo. 2014. The Aace Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocrine Practice. 20 (9): 977–89. doi: 10.4158/EP14280.PS

Garvey W.T., Mechanick J.I., Brett E.M. 2016. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 22 (Supplement 3): 1–203. doi: 10.4158/ep161365.gl.

Global Health Observatory Data Repository. 2013. Report WHO. Geneva: World Health Organization. [cited 2015 Feb 12]. Available from: http://www.euro.who.int/en/health-topics/diseaseprevention/nutrition/country-work/russian-federation2/.

Gonzalez-Carter D., Goode A.E., Fiammengo R. 2016. Inhibition of leptin-ObR interaction does not prevent leptin translocation across a human blood-brain Barrier model. Journal of Neuroendocrinology. 28 (6). doi: 10.1111/jne.12392

Coppari R., Bjorbaek C. 2012. Leptin revisited: its mechanism of action and potential for treating diabetes // Nat. Rev. Drug. Discov. 11 (9): 692–708.

Dedov I.I., Melnichenko G.A., Romantsova T.I. 2016. The strategy of obesity management: the results of All-Russian observational program «Primavera». Obesity and metabolism. 13 (1): 36–44. https://doi.org/10.14341/omet2016136-44

Durrer Schutz D., Busetto L., Dicker D. 2019. European practical and patient-centred guidelines for adult obesity management in primary care. Obes. Facts. Vol. 12 (1): 40–66.

Guo F., Garvey W.T. 2015. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. The Journal of Clinical Endocrinology & Metabolism. 100 (10): 3871–7.

Guzzardi M.A. 2016. Maternal adiposity and infancy growth predict later telomere length: a longitudinal cohort study. J. Obes. 40(7): 1063–1069.

Hans Hauner. 2005. Secretory factors from human adipose tissue and their functional role. Nutrition Society. 64: 163.

Iacobellis G., Barbaro G. 2008. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ /Hormone and Metabolic Research. 40 (7): 442–445.

Kramer C.K., Zinman B., Retnakaran R. 2013. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Annals of internal medicine. 159 (11): 758–769.

Ladabaum U., Mannalithara A., Myer P.A., Singh G. 2014. Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988–2010. Am. J. Med. 127 (8): 717–727. e12. doi: 10.1016/j.amjmed.2014.02.026.

Ling C., Rönn T. Epigenetics in human obesity and type 2 diabetes. 2019. Cell Metab. 29 (5): 1028–1044. doi: 10.1016/j.cmet.2019.03.009.

Mirza M.S. 2011. Obesity, Visceral Fat and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease ISRN. Gastroenterology. 2011: 592404. doi: 10.5402/2011/592404. Epub 2011 Aug 28

Obesity and overweight. Report of a WHO. 2015 [cited 2016 Apr 18]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.

Obesity and overweight. Report of a WHO. 2020 https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

Obesity Prevention and Management. 2019. UMHS. med. umich.edu/1info/FHP/practiceguides/obesity/obesity.pdf.

Ou H.Y., Wang C.Y., Yang Y.C., 2013. The Association between Nonalcoholic Fatty Pancreas Disease and Diabetes. PLoSONE. 8 (5): e62561 https://doi.org/10.1371/journal.pone.0062561.

Oussaada S.M., van Galen K.A., Cooiman M.I. 2019. The pathogenesis of obesity. Metabolism. 2019. 92: 26–36.

Patel L. 2003. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem. Biophys. Res. Commun. 300: 472–476.

Popkin B.M., Du S., Green W.D. 2020. Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships. Obesity Reviews. 1–17. DOI: 10.1111/obr.13128.

Ravinet Trillou C., Delgorge C., Menet C. 2004. CB1 cannabi-noid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28 (4): 640–648.

Reilly M.P. 2005. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 111: 932–939.

Richey J.M., Woolcott O. 2017. Re-visiting the endocannabinoid system and its therapeutic potential in obesity and associated diseases. Curr. Diab. Rep. 17 (10): 99.

Ritter A., Kreis N.N., Louwen F., Yuan J. 2020. Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. Int. J. Mol. Sci. 21 (16): 5793. doi:10.3390/ijms21165793.

Romantseva T.I., Ostrovskaya E.V. 2015. Metabolic healthy obesity: definitions, protective factors, clinical significance. Almanakh klinicheskoy meditsini [Almanac of Clinical Medicine]. (Special Issue 1): 75–86.

Romero-Corral A., Somers V.K., Sierra-Johnson J. 2007. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. European Heart Journal. 28: 2087–2093.

Rossi F., Punzo F., Umano G.R. 2018. Role of cannabinoids in obesity. Int. J. Mol. Sci. 19 (9): 2690. doi: 10.3390/ijms19092690

Schulze M.B. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019; 62 (4): 558–66. doi:10.1007/s00125-018-4787-8.

Senthilingam M. 2021. Covid-19 has made the obesity epidemic worse, but failed to ignite enough action. BMJ. 372: n411. doi:10.1136/ bmj.n411. (Published 04 March 2021)

Su Jong Yu, Won Kim, Donghee Kim. 2015. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver. Disease Medicine. 94 (48): e2159.

Sun K., Kusminski C.M., Scherer P.E. 2011. Adipose tissue remodeling and obesity. J. Clin. Invest. 121 (6): 2094–101.

Wolf Gunter, Ziyadeh Fuad N. Leptin and Renal Fibrosis. 2006. Obesity and the Kidney. Contrib Nephrol. Basel, Karger. 151: 175–183.

Zhi C., Huang J., Wang J. 2019. Connection between gut microbiome and the development of obesity. Eur. J. Clin. Microbiol. Infect. Dis. Jul 31 doi: 10.1007/s10096-019-03623-x.

Zhu L., She Z.-G., Cheng X. 2020. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell. Metab. 31: 1068–77. e3. doi: 10.1016/j.cmet.2020.04.021.